Health Care·Biotechnology·$8.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.68 | N/A | -21.43% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.68 | N/A | -21.43% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Overall, management expressed caution regarding the company's financial outlook. They highlighted ongoing challenges that may impact future performance.
Management did not provide specific revenue guidance for the upcoming quarters.
The company acknowledged challenges in achieving profitability in the near term.
The earnings report indicates that Vaxcyte Inc is facing challenges, as reflected in the missed EPS target. The stock dropped 11.78% following the announcement, likely due to investor concerns over the lack of revenue updates and management's cautious tone. Without clear guidance, investors may remain uncertain about the company's future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
NRG ENERGY INC
May 6, 2022